A committee, the One Wales Medicines Assessment Group (OWMAG) assesses the evidence and makes a recommendation to health board chief executives. This committee comprises representation from all IPFR panels, a lay member, industry representative, finance representative, a clinical pharmacologist and a health economist. Clinical experts and patient groups are invited to attend the OWMAG meeting to set the clinical and patient context.
One Wales decisions will be disseminated to the service following endorsement by the All Wales Medicines Strategy Group (AWMSG) and ratification by Welsh Government.